|Articles|September 26, 2019

Estimating HIV Screening Incidence Among US Citizens

Investigators used national electronic health record data to determine the proportion of American adults who have been tested for HIV.

Both the CDC and the US Preventive Services Task Force recommend population-based screening for HIV at least once in a person’s life. However, new findings are offering disappointing results on how many people may actually get screened.

Using national electronic health record (EHR) information on more than 40 million patients over a 20-year period (1999-2018), researchers have found that the proportion of Americans older than 18 years who have had a prior HIV test could be as low as 6.4%.

The figure is vastly different from national survey estimates indicating that 42.5% of the population has been screened, and the researchers noted these studies have relatively low sample sizes and inherent survey biases. The results were published in Cureus.

“While our estimates were significantly lower than those reported by the CDC, it should be noted that no study has yet determined whether single-item questions on national surveys of HIV screening corroborate with objective evidence of screening,” they wrote.

However, the researchers also poked holes in the validity of current EHR use to determine screening rates, which was used in their research. They used the cloud-based Explorys database, which deidentified and standardized aggregate data from 26 integrated US healthcare systems across all 50 states.

Among the 45.5 million patients, nearly 3 million had evidence of a prior HIV test. The most important predictor of screening was insurance status. However, females, African Americans, and those between the ages of 25 and 34 years old were also more likely to be tested. Previous research has indicated that 25 years old is the optimal for screening people, as screening at that age provides the most favorable clinical outcomes and the best value for money.

The researchers acknowledged that their study was limited by hospitals systems that do not report HIV laboratory data to the EHR used or that use anonymous HIV screening, and that information from patients who receive screening through non-hospital systems, such as county health departments and stand-alone sexually transmitted disease clinics, were not included in the EHR data. They added that the conversion from paper charts to EHRs for the included hospital systems may result in missing data since 1999.

“Although this study reveals the profound limitations of EHR data thus rendering it currently not useful for the study of HIV laboratory data, if these limitations can be addressed nationally, could-based all-payer databases may provide objective, daily up-to-date information on HIV screening daily,” wrote the researchers.

“Until then, studies using EHR or administrative claims data should interpret HIV laboratory data with caution as it may greatly underestimate the proportion of patients screened in the United States,” they concluded.

This article originally appeared on AJMC.com.


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.